Remarkably, while C188-9 treatment significantly alleviated the severity of colitis in the eEF2K KO group, this STAT3 inhibitor did not affect the severity of the disease in the WT group, as determined by body weight (Fig. 7a), colon size (Fig. 7b, c), and pathologic score (Fig. 7d, e). This evidence concerns the gene EEF2K and colitis.